{'52WeekChange': 0.32546115,
 'SandP52WeekChange': None,
 'address1': '333 Oyster Point Boulevard',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 17.93,
 'askSize': 800,
 'averageDailyVolume10Day': 155975,
 'averageVolume': 295244,
 'averageVolume10days': 155975,
 'beta': None,
 'beta3Year': None,
 'bid': 17.9,
 'bidSize': 1200,
 'bookValue': 4.699,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.21,
 'dayLow': 17.535,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -16.719,
 'enterpriseToRevenue': 8.705,
 'enterpriseValue': 890994816,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 20.32257,
 'fiftyTwoWeekHigh': 23.95,
 'fiftyTwoWeekLow': 8.81,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 19575424,
 'forwardEps': -1.43,
 'forwardPE': -12.524476,
 'fromCurrency': None,
 'fullTimeEmployees': 186,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.2831,
 'heldPercentInstitutions': 0.57357,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ngmbio.com',
 'longBusinessSummary': 'NGM Biopharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, engages in the discovery '
                        'and development of novel therapeutics for the '
                        'treatment of cardio-metabolic, liver, oncologic, and '
                        "ophthalmic diseases. The company's product candidates "
                        'include Aldafermin, an engineered variant of the '
                        'FGF19 human hormone in Phase 2b clinical trials for '
                        'the treatment of non-alcoholic steatohepatitis '
                        '(NASH); NGM313, an agonistic antibody that activates '
                        'fibroblast growth factor receptor 1c-beta-klotho, '
                        'which is in Phase 1b clinical trial for use in the '
                        'treatment of type 2 diabetes and NASH; and NGM395, '
                        'which is engineered variant of the GDF15 human '
                        'hormone for use in the treatment of metabolic '
                        'syndrome. Its products under development also '
                        'comprise NGM120, an inhibitory antibody binding glial '
                        'cell-derived neurotrophic factor receptor alpha-like '
                        'that is in Phase 1 clinical trials to inhibit the '
                        'effects of elevated GDF15 levels on cancer '
                        'anorexia/cachexia syndrome; NGM217, an antibody in '
                        'Phase 1 clinical trials to restore pancreatic islet '
                        'function and increase insulin production in patients '
                        'with diabetes; and NGM621, an antibody in Phase 1 '
                        'clinical trials to decrease levels of a protein '
                        'implicated in the dry form of AMD. The company has '
                        'research collaboration, product development, and '
                        'license agreements with Merck Sharp & Dohme Corp. NGM '
                        'Biopharmaceuticals, Inc. was incorporated in 2007 and '
                        'is headquartered in South San Francisco, California.',
 'longName': 'NGM Biopharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1220421504,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_41080995',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -53642000,
 'nextFiscalYearEnd': 1640908800,
 'open': 17.56,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 243 5555',
 'previousClose': 17.96,
 'priceHint': 2,
 'priceToBook': 3.8114493,
 'priceToSalesTrailing12Months': 11.923302,
 'profitMargins': -0.52407,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.21,
 'regularMarketDayLow': 17.535,
 'regularMarketOpen': 17.56,
 'regularMarketPreviousClose': 17.96,
 'regularMarketPrice': 17.56,
 'regularMarketVolume': 250113,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 68141904,
 'sharesPercentSharesOut': 0.0545,
 'sharesShort': 3713492,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3510946,
 'shortName': 'NGM Biopharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1571,
 'shortRatio': 10.08,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'NGM',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.82,
 'twoHundredDayAverage': 17.852842,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '482d48b8-37e0-3bcb-98ab-fe5eb295a67c',
 'volume': 250113,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ngmbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}